Vir Biotechnology, Inc. VIR reported worse-than-expected Q4 results.
Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s quarterly sales came in at $49.41 million, versus estimates of $97.30 million.
Vir Biotechnology shares gained 5.1% to $24.00 in pre-market trading.
These analysts made changes to their price targets on Vir Biotechnology following the release of results.
JP Morgan cut the price target on Vir Biotechnology from $35 to $34. JP Morgan analyst Eric Joseph upgraded the stock from Neutral to Overweight.
HC Wainwright & Co. slashed the price target on Vir Biotechnology from $125 to $100. HC Wainwright & Co. analyst Patrick Trucchio maintained a Buy rating.
(C) 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: EarningsNewsPrice TargetPre-Market OutlookMarketsAnalyst RatingsTrading IdeasPT Changes
